Chronic organic manganese administration in the rat does not damage dopaminergic nigrostriatal neurons.
In an attempt to produce an animal model of Parkinson's disease, we injected rats repeatedly with high doses of methylcyclopentadienyl manganese tricarbonyl (MMT), a compound which has been reported to lower striatal dopamine content in mice. Chronic MMT administration for up to 5 months, even though it produced a substantial elevation in brain manganese content during the period of exposure, did not destroy dopaminergic nigrostriatal neurons. This was assessed by measurements of tyrosine hydroxylase activity and contents of dopamine and its metabolites in the striatum, and by histological examination of the substantia nigra. Our results differ from those of others who administered manganese chloride in drinking water to rats. This discrepancy is unlikely to be a consequence of differences in duration of exposure or route of administration. It could be due to our having used an organic rather than an inorganic manganese compound, or to a species difference in vulnerability to organic manganese between rats and mice.
Yong
V W
VW
Perry
T L
TL
Godolphin
W J
WJ
Jones
K A
KA
Clavier
R M
RM
Ito
M
M
Foulks
J G
JG
D000818:Animals; D001927:Brain Diseases / Q000139:chemically induced; D003342:Corpus Striatum / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000502:physiology*; D005260:Female; D020149:Manganese Poisoning; D009942:Organometallic Compounds / Q000633:toxicity*; D010300:Parkinson Disease; D051381:Rats; D011919:Rats, Inbred Strains; D013378:Substantia Nigra; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D009942:Organometallic Compounds; C009907:2-methylcyclopentadienyl manganese tricarbonyl; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine